SGLT2 and GLP-1 medications unlock new potential in CKM care

Recent data reveal a striking paradox: While 73% of endocrinologists prescribe glucose-lowering medications, fewer than 10% of nephrologists do. This difference highlights a critical opportunity. Historically, nephrologists have deferred metabolic management to primary care or endocrinology, but the interconnected reality of cardiovascular-kidney-metabolic (CKM) syndrome requires a more

Raccontata dahealio.com